LEVOTHYROXINE SODIUM | A076187 | MYLAN PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition Request from LACHMAN CONSULTANT SERVICES INC FDA-2015-P-0403 · 7 docket documents Lachman Consultant Services, Inc. filed this citizen petition on behalf of a client requesting that the FDA determine whether Lloyd's LEVOTHROID (levothyroxine sodium) Tablets in twelve dosage strengths, approved under NDA 021116, were voluntarily withdrawn for safety or effectiveness reasons, and i | 505(q) | 2015-02-06 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1084
per ea
Lowest NADAC/Unit
$0.0362
per ea
Brand NDCs
0
Generic NDCs
33
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378182177LEVOTHYROXINE 300 MCG TABLET | $0.1084 | EA | Generic | — | 2026-06-17 |
| 00378181977LEVOTHYROXINE 200 MCG TABLET | $0.0806 | EA | Generic | — | 2026-06-17 |
| 00378181910LEVOTHYROXINE 200 MCG TABLET | $0.0806 | EA | Generic | — | 2026-06-17 |
| 00378181777LEVOTHYROXINE 175 MCG TABLET | $0.0800 | EA | Generic | — | 2026-06-17 |
| 00378181710LEVOTHYROXINE 175 MCG TABLET | $0.0800 | EA | Generic | — | 2026-06-17 |
| 42292004020LEVOTHYROXINE 175 MCG TABLET | $0.0800 | EA | Generic | — | 2026-06-17 |
Showing 6 of 33 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.